Grifols S.A. ADR Stock
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Grifols S.A. ADR | - | -3.333% | 4.505% | -11.450% | -37.297% | -61.188% | -65.269% |
| Beximco Pharmaceuticals Ltd. GDR | -0.930% | 2.381% | -1.376% | -4.444% | -2.273% | -55.670% | -21.818% |
| Cellectar BioSciences Inc. | -1.400% | -2.083% | -21.667% | 110.448% | 23.684% | -77.258% | - |
| Arca Biopharma | -5.290% | 5.844% | 98.176% | 75.741% | 109.646% | 10.884% | -94.250% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "sell" rating.
Show more
Ratings data for GRFS provided by MarketBeat